Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ORICthis companyORIC Pharmaceuticals, Inc.	$8.84	-5.56×	1.87×	0×	-5.33×	-96.2%	0.0%	0.0%	0.0%	-33.7%	-36.3%	-15.9%	0.03×	0.27×	0×	14.13×	0.0%	1	21.2	2	C
AVBPArriVent BioPharma, Inc.	$13.65	-4.66×	2.52×	0×	-4.38×	-92.2%	0.0%	0.0%	0.0%	-54.1%	-57.8%	-20.8%	0×	0.27×	0×	12.83×	0.0%	2	12.15	2	C+
CRVSCorvus Pharmaceuticals, Inc.	$10.66	-40.53×	9.93×	0×	-39.82×	-99.8%	0.0%	0.0%	0.0%	-25.0%	-69.1%	-5.4%	0.02×	0.24×	0×	6.21×	0.0%	2	32.84	2	C
ELVNEnliven Therapeutics, Inc.	$49.74	-8.42×	1.9×	0×	-7.48×	-96.2%	0.0%	0.0%	0.0%	-22.6%	-26.0%	-8.1%	0×	0.95×	0×	28.66×	0.0%	2	130.13	2	C+
JANXJanux Therapeutics, Inc.	$17.14	-7.54×	0.89×	85.51×	-7.39×	-118.0%	79.7%	-1576.7%	-1136.3%	-11.9%	-16.0%	-9.7%	0.02×	0.27×	0×	39.04×	0.0%	3	8.27	2	C+
MGNXMacroGenics, Inc.	$2.38	-1.36×	1.83×	0.68×	-2.54×	-2714.5%	71.1%	-48.7%	-49.9%	-134.2%	-33.0%	-81.6%	1.92×	-0.83×	-8.56×	5.1×	0.0%	1	-4.43	1	D+
Peer median	—	-7.54×	1.9×	0×	-7.39×	-99.8%	0.0%	0.0%	0.0%	-25.0%	-33.0%	-9.7%	0.02×	0.27×	0×	12.83×	0.0%	2	12.15	2	—